Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions

Chinese Medicine

Review

Xing-yu Lu¹  Yi-xuan Yu¹  Hui-jing Dong¹  Xu Zhang¹  Zi-xin Hu¹  Zhe-ning Liu¹  Jia-bin Zheng²  Hui-juan Cui²  Shuo Wang² 

[1] Graduate School, Beijing University of Chinese Medicine, 100029, Beijing, China;Oncology Department of Integrative Medicine, China-Japan Friendship Hospital, No.2 Yinghua East Road, Chaoyang District, 100029, Beijing, China;Oncology Department of Integrative Medicine, China-Japan Friendship Hospital, No.2 Yinghua East Road, Chaoyang District, 100029, Beijing, China;

关键词: Traditional Chinese Medicine;    Immune checkpoint inhibitor;    Immunotherapy;    Tumor microenvironment;   

DOI  :  10.1186/s13020-023-00751-7

 received in 2022-12-06, accepted in 2023-04-13,  发布年份 2023

来源: Springer

【 摘 要 】

Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 32